CA3233206A1 — Pharmaceutical composition containing triazine derivative
Assigned to Hokkaido University NUC · Expires 2023-04-06 · 3y expired
What this patent protects
The present invention provides a pharmaceutical composition containing a compound that exhibits a coronavirus growth inhibitory activity. A pharmaceutical composition containing a compound represented by the formula (wherein: Y is N; R1 represents an optionally substituted aromat…
USPTO Abstract
The present invention provides a pharmaceutical composition containing a compound that exhibits a coronavirus growth inhibitory activity. A pharmaceutical composition containing a compound represented by the formula (wherein: Y is N; R1 represents an optionally substituted aromatic heterocyclic group; R2 represents an optionally substituted 6-membered aromatic carbon ring group; R3 represents an optionally substituted aromatic heterocyclic group; -X- is -NH-; m is 0 or 1; R5a represents a hydrogen atom; R5b represents a hydrogen atom; n is 1; R4a represents a hydrogen atom; and R4b represents a hydrogen atom) or a pharmaceutically acceptable salt thereof.
Drugs covered by this patent
- Paxlovid (Copackaged) (Nirmatrelvir) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.